Related Experiment Video
Updated: May 29, 2026
Monitoring the Wall Mechanics During Stent Deployment in a Vessel
Published on: May 8, 2012
Biodegradable stents and occluders in CHD: current evidence, biomechanical constraints, and translational challenges
Sercin Ozkok1,2, Banu Kose3, Ilker Kemal Yucel4
1Department of Radiology, https://ror.org/05grcz969University of Health Science Basaksehir Cam and Sakura City Hospital, Türkiye.
Insights
Biodegradable devices offer temporary support for congenital heart disease (CHD), potentially reducing lifelong complications from permanent implants. However, challenges remain in balancing structural integrity with degradation for pediatric use.
Area of Science:
- Biomaterials Science
- Pediatric Cardiology
- Medical Device Engineering
Background:
- Congenital heart disease (CHD) frequently necessitates device implantation in children, posing challenges due to somatic growth and hemodynamic changes.
- Permanent metallic stents and nitinol occluders, while effective, can complicate future interventions, imaging, and growth-related remodeling.
- Biodegradable implants aim to provide temporary mechanical support and resorb over time, minimizing long-term foreign material burden.
Purpose of the Study:
- To review the rationale, current evidence, biomechanical constraints, and translational challenges of biodegradable stents and occluders in pediatric CHD.
- To assess the potential of biodegradable devices to reduce the long-term impact of permanent implants in growing patients.
- To identify the hurdles in adapting biodegradable technology from adult applications to congenital and pediatric settings.
Main Methods:
- Literature review of existing studies on biodegradable stents and occluders in CHD.
- Analysis of biomechanical requirements and degradation profiles for pediatric applications.
- Evaluation of clinical experience and translational challenges for biodegradable devices in congenital practice.
Main Results:
- Biodegradable septal occluders have more clinical experience and are closer to routine use in CHD.
- Biodegradable vascular stents for CHD are largely investigational, lacking sufficient long-term outcome data for widespread adoption.
- Translating biodegradable technology requires balancing early structural integrity with predictable degradation and compatibility with somatic growth, which differs from adult coronary applications.
Conclusions:
- Biodegradable implants hold promise for CHD by offering temporary support and reducing permanent foreign material.
- Significant challenges exist in adapting biodegradable technology for pediatric CHD, including ensuring structural integrity during growth and predictable resorption.
- Further long-term studies in pediatric and congenital populations are essential before biodegradable devices can be recommended as standard alternatives to permanent implants.
Abstract:
Congenital heart disease (CHD) often requires device implantation during childhood, when somatic growth and changing haemodynamics place particular demands on permanent implants. Metallic stents and nitinol occluders are effective, but their lifelong persistence can complicate repeat interventions, limit imaging surveillance, and interfere with growth-related remodelling. This review examines the rationale, current evidence, biomechanical constraints, and translational challenges of biodegradable stents and occluders in CHD. These devices aim to provide temporary mechanical support followed by controlled resorption, thereby reducing the burden of permanent foreign material and preserving future interventional options. Translation to congenital practice is, however, not straightforward, as early structural integrity must be balanced against predictable degradation, adequate endothelialisation, and compatibility with somatic growth. Experience from adult coronary bioresorbable scaffolds cannot be directly extrapolated to paediatric anatomies or timelines. Biodegradable septal occluders have accumulated more clinical experience and appear closer to routine use, whereas biodegradable vascular stents remain largely investigational and lack sufficient long-term outcome data to support broader adoption. Further long-term studies in paediatric and congenital populations are needed before biodegradable implants can be recommended as standard alternatives to permanent devices in CHD.
